January 2025 marked a watershed moment in European pharmaceutical regulation: the EU HTA Regulation (2021/2282) entered full force, fundamentally reshaping how medicines are assessed and reimbursed across 27 Member States. For pharmaceutical companies, this means a single misstep in joint clinical assessment can now cascade into market access delays across the entire continent.